A Loading Dose of Dexmedetomidine With Constant Infusion Inhibits Intraoperative Neuromonitoring During Thoracic Spinal Decompression Surgery: A Randomized Prospective Study

Tun Liu, Yue Qin, Huaguang Qi, Zhenguo Luo, Liang Yan, Pengfei Yu, Buhuai Dong, Song‐Chuan Zhao, Xucai Wu, Zhen Chang, Zhian Liu, Xuemei Liu, Tao Yuan, Houkun Li, Xiao Li, Gang WangFrontiers in Pharmacology 2022 · DOI

Abstract

Background: The effect of a bolus dose of dexmedetomidine on intraoperative neuromonitoring (IONM) parameters during spinal surgeries has been variably reported and remains a debated topic. Methods: A randomized, double-blinded, placebo-controlled study was performed to assess the effect of dexmedetomidine (1 μg/kg in 10 min) followed by a constant infusion rate on IONM during thoracic spinal decompression surgery (TSDS). A total of 165 patients were enrolled and randomized into three groups: T group (control), D1 group (constant infusion), and D2 group (loading dose followed by infusion). Results: In the D2 group, within-group analysis showed suppressive effects on IONM parameters compared with baseline after a bolus dose. The D2 group also showed inhibitory effects compared with both the D1 and T groups, including a statistically significant decrease in SSEP and MEP amplitude and an increase in SSEP latency. No significance was found between the T and D1 groups. Conclusion: Dexmedetomidine delivered in a loading dose can significantly inhibit IONM parameters in TSDS. Special attention should be paid to the timing of a bolus dose; however, a constant infusion does not exert inhibitory effects.

Introduction

Thoracic spinal decompression surgery (TSDS) carries a high risk of permanent neurological injury or paralysis. To mitigate this, surgeons utilize Intraoperative Neuromonitoring (IONM), specifically Somatosensory Evoked Potentials (SSEP) and Motor Evoked Potentials (MEP), to provide real-time feedback on spinal cord function.

Dexmedetomidine (DEX) is a common anesthetic adjuvant used to reduce opioid and propofol requirements. However, its impact on IONM signals is debated. If DEX suppresses these signals, it could lead to "false positives"—suggesting nerve damage that isn't occurring—potentially causing surgeons to halt necessary procedures. This study investigates whether the administration method (a rapid loading dose versus a slow constant infusion) is the deciding factor in signal interference.

Methods and Patient Cohort

The researchers conducted a randomized, double-blinded, placebo-controlled trial with 165 patients undergoing TSDS. All patients received Total Intravenous Anesthesia (TIVA) using propofol and remifentanil.

CONSORT flow diagram illustrating patient enrollment, randomization into three groups (T, D1, D2), and final analysis.

Patients were randomized into three groups:

  • T Group (Control): Received a saline bolus and saline infusion.
  • D1 Group: Received a saline bolus followed by a constant DEX infusion (0.5 μg/kg/h).
  • D2 Group: Received a DEX loading dose (1 μg/kg over 10 min) followed by a constant infusion (0.5 μg/kg/h).

The team measured SSEP and MEP at multiple time points, starting from a baseline before drug administration through the end of surgery, focusing on changes in amplitude (signal strength) and latency (signal speed).

Key Results

The study revealed that the method of delivery is critical to maintaining IONM integrity. The most significant finding was that the rapid loading dose (bolus) in the D2 group caused transient but significant signal suppression, while the constant infusion in the D1 group did not.

MEP and SSEP Suppression

In the D2 group, SSEP latency increased by 5.50%, and SSEP amplitude decreased by 24.75% compared to baseline. Furthermore, the D2 group saw a 27.13% decrease in MEP amplitude shortly after the loading dose was administered.

Graph showing the significant decrease in MEP amplitude baseline for the D2 Group (loading dose) compared to the T and D1 groups at early time points.

These suppressive effects in the D2 group were statistically significant compared to both the control (T) and constant infusion (D1) groups. Crucially, the D1 group showed no significant difference in signals compared to the control group, suggesting that a constant infusion of 0.5 μg/kg/h is a "safe zone" for neuromonitoring.

Discussion and Clinical Implications

The suppressive window in the D2 group (approximately 10–25 minutes) often coincides with the start of surgical decompression—the exact moment when clear IONM signals are most vital. DEX likely inhibits synaptic transmission by activating the descending noradrenergic system, leading to postsynaptic hyperpolarization. A high-concentration bolus triggers this effect much more intensely than a steady, low-level infusion.

Additionally, the loading dose caused short-lived hemodynamic instability, including drops in Mean Arterial Pressure (MAP) and Heart Rate (HR). While the study was limited by its narrow age demographic (18–60 years) and the frequency of MEP recordings, the results provide clear guidance for clinical practice.

Conclusion

Dexmedetomidine is a useful anesthetic adjuvant, but its delivery timing is critical. A loading dose can inhibit IONM parameters enough to approach clinical warning criteria, potentially triggering false alarms. To avoid interference with neurological monitoring during critical phases of spinal surgery, clinicians should favor constant infusion over bolus administration.

Summary updated

Abstract

<b>Background:</b> The effect of a bolus dose of dexmedetomidine on intraoperative neuromonitoring (IONM) parameters during spinal surgeries has been variably reported and remains a debated topic. <b>Methods:</b> A randomized, double-blinded, placebo-controlled study was performed to assess the effect of dexmedetomidine (1 μg/kg in 10 min) followed by a constant infusion rate on IONM during thoracic spinal decompression surgery (TSDS). A total of 165 patients were enrolled and randomized into three groups. One group received propofol- and remifentanil-based total intravenous anesthesia (TIVA) (T group), one group received TIVA combined with dexmedetomidine at a constant infusion rate (0.5 μg kg<sup>-1</sup> h<sup>-1</sup>) (D<sub>1</sub> group), and one group received TIVA combined with dexmedetomidine delivered in a loading dose (1 μg kg<sup>-1</sup> in 10 min) followed by a constant infusion rate (0.5 μg kg<sup>-1</sup> h<sup>-1</sup>) (D<sub>2</sub> group). The IONM data recorded before test drug administration was defined as the baseline value. We aimed at comparing the parameters of IONM. <b>Results:</b> In the D<sub>2</sub> group, within-group analysis showed suppressive effects on IONM parameters compared with baseline value after a bolus dose of dexmedetomidine. Furthermore, the D<sub>2</sub> group also showed inhibitory effects on IONM recordings compared with both the D<sub>1</sub> group and the T group, including a statistically significant decrease in SSEP amplitude and MEP amplitude, and an increase in SSEP latency. No significance was found in IONM parameters between the T group and the D<sub>1</sub> group. <b>Conclusion:</b> Dexmedetomidine delivered in a loading dose can significantly inhibit IONM parameters in TSDS. Special attention should be paid to the timing of a bolus dose of dexmedetomidine under IONM. However, dexmedetomidine delivered at a constant speed does not exert inhibitory effects on IONM data.
BibTeX
@inproceedings{liu2022loading,
  author = {Tun Liu and Yue Qin and Huaguang Qi and Zhenguo Luo and Liang Yan and Pengfei Yu and Buhuai Dong and Song‐Chuan Zhao and Xucai Wu and Zhen Chang and Zhian Liu and Xuemei Liu and Tao Yuan and Houkun Li and Xiao Li and Gang Wang},
  title = {{A Loading Dose of Dexmedetomidine With Constant Infusion Inhibits Intraoperative Neuromonitoring During Thoracic Spinal Decompression Surgery: A Randomized Prospective Study}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.840320},
}
Figure